Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Ведение пациенток с воспалительными заболеваниями органов малого таза
Ведение пациенток с воспалительными заболеваниями органов малого таза
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Обзор Европейского руководства Международного союза по борьбе с инфекциями,
передаваемыми половым путем (IUSTI)
передаваемыми половым путем (IUSTI)
Полный текст
Список литературы
1. Bevan CD, Johal BJ, Mumtaz G et al. Clinical, laparoscopic and microbiological findings in acute salpingitis: report on a United Kingdom cohort. Brit J Obstet Gynaecol 1995; 102 (5): 407–14.
2. Altunyurt S, Demir N, Posaci C. A randomized controlled trial of coil removal prior to treatment of pelvic inflammatory disease. Eur J Obstet Gynecol Reprod Biol 2003; 107: 81–4.
3. Bradshaw CS, Jensen JS, Tabrizi SN et al. Azithromycin failure in Mycoplasma genitalium urethritis. Emerg Infect Dis 2006; 12 (7): 1149–52.
4. Foulds G, Johnson RB. Selection of dose regimens of azithromycin. J Antimicrob Chem 1993; 31 (Suppl. E): 39–50.
5. Judlin P, Liao Q, Liu Z et al. Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG: An Int J Obstet Gynaecol 2010;117(12):1475–84.
6. Heystek MJ, Ross JDC. PID Study Group. A randomised double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease. Int J STD AIDS 2009; 20: 690–5.
7. Lanjouw E, Ossewaarde JM, Stary A et al. European guideline for the management ofChlamydia trachomatis infections. Int J STD AIDS 2010; 21 (11): 729–37.
8. CDC. Sexually Transmitted Diseases Treatment Guidelines 2002. MMWR – Morbidity & Mortality Weekly Report 2002; 55 (RR-6): 1–84.
2. Altunyurt S, Demir N, Posaci C. A randomized controlled trial of coil removal prior to treatment of pelvic inflammatory disease. Eur J Obstet Gynecol Reprod Biol 2003; 107: 81–4.
3. Bradshaw CS, Jensen JS, Tabrizi SN et al. Azithromycin failure in Mycoplasma genitalium urethritis. Emerg Infect Dis 2006; 12 (7): 1149–52.
4. Foulds G, Johnson RB. Selection of dose regimens of azithromycin. J Antimicrob Chem 1993; 31 (Suppl. E): 39–50.
5. Judlin P, Liao Q, Liu Z et al. Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG: An Int J Obstet Gynaecol 2010;117(12):1475–84.
6. Heystek MJ, Ross JDC. PID Study Group. A randomised double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease. Int J STD AIDS 2009; 20: 690–5.
7. Lanjouw E, Ossewaarde JM, Stary A et al. European guideline for the management ofChlamydia trachomatis infections. Int J STD AIDS 2010; 21 (11): 729–37.
8. CDC. Sexually Transmitted Diseases Treatment Guidelines 2002. MMWR – Morbidity & Mortality Weekly Report 2002; 55 (RR-6): 1–84.
2. Altunyurt S, Demir N, Posaci C. A randomized controlled trial of coil removal prior to treatment of pelvic inflammatory disease. Eur J Obstet Gynecol Reprod Biol 2003; 107: 81–4.
3. Bradshaw CS, Jensen JS, Tabrizi SN et al. Azithromycin failure in Mycoplasma genitalium urethritis. Emerg Infect Dis 2006; 12 (7): 1149–52.
4. Foulds G, Johnson RB. Selection of dose regimens of azithromycin. J Antimicrob Chem 1993; 31 (Suppl. E): 39–50.
5. Judlin P, Liao Q, Liu Z et al. Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG: An Int J Obstet Gynaecol 2010;117(12):1475–84.
6. Heystek MJ, Ross JDC. PID Study Group. A randomised double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease. Int J STD AIDS 2009; 20: 690–5.
7. Lanjouw E, Ossewaarde JM, Stary A et al. European guideline for the management ofChlamydia trachomatis infections. Int J STD AIDS 2010; 21 (11): 729–37.
8. CDC. Sexually Transmitted Diseases Treatment Guidelines 2002. MMWR – Morbidity & Mortality Weekly Report 2002; 55 (RR-6): 1–84.
________________________________________________
2. Altunyurt S, Demir N, Posaci C. A randomized controlled trial of coil removal prior to treatment of pelvic inflammatory disease. Eur J Obstet Gynecol Reprod Biol 2003; 107: 81–4.
3. Bradshaw CS, Jensen JS, Tabrizi SN et al. Azithromycin failure in Mycoplasma genitalium urethritis. Emerg Infect Dis 2006; 12 (7): 1149–52.
4. Foulds G, Johnson RB. Selection of dose regimens of azithromycin. J Antimicrob Chem 1993; 31 (Suppl. E): 39–50.
5. Judlin P, Liao Q, Liu Z et al. Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG: An Int J Obstet Gynaecol 2010;117(12):1475–84.
6. Heystek MJ, Ross JDC. PID Study Group. A randomised double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease. Int J STD AIDS 2009; 20: 690–5.
7. Lanjouw E, Ossewaarde JM, Stary A et al. European guideline for the management ofChlamydia trachomatis infections. Int J STD AIDS 2010; 21 (11): 729–37.
8. CDC. Sexually Transmitted Diseases Treatment Guidelines 2002. MMWR – Morbidity & Mortality Weekly Report 2002; 55 (RR-6): 1–84.
Авторы
М.А.Гомберг
Московский научно-практический центр дерматовенерологии и косметологии
Московский научно-практический центр дерматовенерологии и косметологии
________________________________________________
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.